查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984151

生物製造領域病毒檢測與定量市場：2026-2032年全球市場預測（按產品、技術、檢體類型、應用和最終用戶分類）

Biomanufacturing Viral Detection & Quantification Market by Product, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年生物製造領域病毒檢測和定量市場價值為 16.3 億美元，預計到 2026 年將成長至 19.7 億美元，複合年成長率為 24.14%，到 2032 年將達到 74.4 億美元。

主要市場統計數據
基準年 2025 16.3億美元
預計年份：2026年 19.7億美元
預測年份 2032 74.4億美元
複合年成長率 (%) 24.14%

詳細介紹先進的病毒檢測和定量技術如何成為現代生物製造品質和營運韌性的基礎。

隨著精準檢測技術從實驗室走向受監管的生產環境，支持病毒檢測和定量分析的生物製造格局正在迅速演變。分子診斷技術的進步，結合自動化和數位分析，正在推動更嚴格的污染控制、更快的產品放行流程以及更緊密的上游工程和下游品質系統協調。各組織越來越認知到，檢測和定量技術不僅僅是實驗室工具，更是保護產品安全、最佳化批次週轉以及滿足日益嚴格的監管要求的戰略手段。

CRISPR、數位 PCR、次世代定序和自動化技術的整合如何從根本上重塑病毒檢測工作流程、品質策略和監管應對措施。

病毒檢測和定量領域正經歷著變革，這得益於技術創新、監管重點以及生物製造領域不斷湧現的應用案例。諸如基於 CRISPR 的檢測平台和數位 PCR 等快速成熟的技術，正以適用於高可靠性環境的形式實現單分子水平的靈敏度；而次世代定序平台則提供了全面的基因組解析度，從而革新了根本原因分析和病毒安全性檢測。同時，免疫檢測技術的改進和側向層析技術的創新，持續為常規監測提供經濟高效的高通量篩檢方案。

評估美國分階段關稅措施對關鍵資產採購、供應商認證和供應鏈韌性的營運和策略影響。

美國2025年實施的累積關稅措施，為病毒檢測和定量分析所用儀器、試劑和專用耗材的籌資策略帶來了多方面的複雜性。這些關稅提高了進口診斷平台和某些試劑的相對成本，迫使採購團隊重新評估其供應商組合、庫存政策和認證流程。因此，製造商和實驗室正努力在短期成本壓力與維持檢驗的工作流程以及確保關鍵材料不間斷供應的基本需求之間取得平衡。

深入了解將儀器、試劑生態系統、技術、應用、最終用戶和檢體類型與策略性檢測選擇和採購聯繫起來的全面細分。

產品細分分析表明，決策越來越受到調整分析能力以滿足特定應用需求的驅動。儀器和系統包括 CRISPR 檢測系統、數位 PCR 系統、免疫檢測分析儀、次世代定序平台、即時PCR系統和聚合酵素連鎖反應熱迴圈儀，每種產品在靈敏度、通量和整合度方面都具有獨特的性能特徵。試劑和試劑盒包括免疫檢測、NGS樣品製備試劑盒、PCR 預混液、RNA 萃取試劑盒和定序試劑，所有這些都對檢測的一致性和批間重複性至關重要。軟體和服務透過提供資料管理、演算法分析和驗證支持，完善了產品環境，滿足了受法規環境的需求。

美洲、歐洲、中東和非洲以及亞太地區的不同區域因素如何影響與偵測能力相關的採購、驗證和供應鏈策略？

區域趨勢正在影響病毒檢測和定量能力的需求模式和供應鏈策略。在美洲，創新中心和密集的合約研發生產機構 (CDMO) 網路正在推動對高通量平台、先進定序和高精度定量方法的需求，以支援複雜的生物製劑研發管線。此外，快速的監管政策澄清和營運擴充性在該地區至關重要，這會影響供應商的選擇和驗證計畫。

儀器製造商、試劑專家和平台創新公司之間的策略競爭動態影響夥伴關係、驗證服務和長期採購決策。

病毒檢測和定量生態系統的競爭動態呈現成熟儀器供應商、試劑專家和新興平台創新者並存的態勢。領先的儀器製造商持續投資於平台整合，透過整合分子、定序和免疫檢測等多種分析方法，提供更廣泛的分析範圍，以滿足科研機構和受監管生產客戶的需求。同時，專業的試劑和試劑盒供應商則專注於配方一致性、批次控制和法規文件，以支援GMP環境下的檢驗工作流程。Start-Ups和成長型企業正不斷突破界限，利用基於CRISPR的檢測方法、奈米孔測序技術的進步以及軟體主導的分析技術，力求更快地解決問題並提供更具實用價值的資料集。

為生物製造領導者提供具體且有影響力的建議，以增強檢測驗證、供應商多元化、自動化互通性和監管資料完整性。

產業領導者應優先考慮一系列切實可行的舉措，以提升整個病毒檢測和定量專案的分析穩健性、供應鏈韌性和合應對力。首先，建立協調品質、生產和分析開發團隊的跨職能管治結構，可以打破部門壁壘，加速檢測方法選擇、變更管理和技術轉移的決策。讓負責人從檢驗計畫的早期階段就參與其中，可以確保偵測效能標準符合放行要求，並減少後續環節可能出現的意外問題。

採用嚴謹的混合方法研究途徑，結合相關人員訪談、技術文獻整合、與監管要求的協調以及基於情境的供應鏈分析。

本分析的調查方法透過系統地結合定性和定量證據，提供了一個穩健且實用的觀點。我們透過對研究總監、品質保證經理、採購經理和技術專家的訪談收集了關鍵訊息，這些訪談深入探討了平台性能、驗證挑戰和供應商趨勢。基於這些第一手資訊，我們識別出了不同終端用戶和應用場景下通用的挑戰和推動因素。

一份權威的綜合分析報告，重點闡述了綜合檢測策略、供應商韌性和先進分析如何決定生物製造的成功和監管準備。

總之，病毒檢測和定量不再是可有可無的活動，而是生物製造品質和運作策略的核心要素。高靈敏度的分子檢測工具、自動化工作流程以及先進分析技術的整合，正在切實改善污染控制、批次放行流程和監管可追溯性。同時，不斷變化的貿易政策和日益複雜的供應鏈要求企業合格開展供應商資格認證、制定靈活的驗證方案，並投資於可互通的平台，以確保營運的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製造中的病毒檢測和定量市場：按產品分類

  • 設備和系統
    • CRISPR檢測系統
    • 免疫檢測分析儀
    • 聚合酵素連鎖反應熱迴圈儀
  • 試劑和試劑盒
  • 軟體服務

第9章：生物製造中的病毒檢測和定量市場：按技術分類

  • CRISPR技術
  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 次世代定序
    • Illumina定序
    • 離子流定序
    • 奈米孔定序
  • 聚合酵素鏈鎖反應
    • 常規PCR
    • 數位PCR
    • 即時PCR

第10章：生物製造中病毒檢測與定量市場—樣本類型

  • 血液/血漿
  • 環境樣品
  • 呼吸道檢體
  • 組織樣本

第11章：生物製造中的病毒檢測和定量市場：按應用領域分類

  • 基因治療的品管
  • 出於研究目的
  • 疫苗研發
  • 病毒量監測
  • 病毒安全測試

第12章：生物製造領域的病毒檢測與定量市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 診斷檢測實驗室
  • 醫院和診所
  • 製藥和生物技術公司

第13章：生物製造領域病毒檢測與定量市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物製造領域病毒檢測與量化市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製造領域病毒檢測與定量市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製造領域病毒檢測與量化市場

第17章：中國生物製造領域病毒檢測與量化市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Avantor, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioReliance Corporation
  • Creative Diagnostics, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • FUJIFILM Diosynth Biotechnologies, Inc.
  • Genscript Biotech Corporation
  • Illumina, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Norgen Biotek Corp.
  • Pall Corporation
  • PerkinElmer, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Roche Holding AG
  • Sartorius AG
  • SGS Societe Generale de Surveillance SA
  • Takara Holdings, Inc.
  • Thermo Fisher Scientific Inc.
  • Virapur, LLC
Product Code: MRR-5C6F41F5AF8D

The Biomanufacturing Viral Detection & Quantification Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.97 billion in 2026, with a CAGR of 24.14%, reaching USD 7.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.97 billion
Forecast Year [2032] USD 7.44 billion
CAGR (%) 24.14%

An in-depth introduction to how advanced viral detection and quantification technologies are becoming foundational to modern biomanufacturing quality and operational resilience

The biomanufacturing environment that supports viral detection and quantification is undergoing rapid evolution as precision assays move from research benches into regulated production environments. Advances in molecular diagnostics, coupled with automation and digital analytics, are driving more robust contamination control, accelerated product release workflows, and tighter integration between upstream and downstream quality systems. Organizations increasingly recognize that detection and quantification technologies are not discrete laboratory tools but strategic levers to protect product safety, optimize batch turnaround, and satisfy intensified regulatory expectations.

In practice, this means cross-functional teams must harmonize assay selection, sample handling procedures, and data governance to achieve reproducible, auditable results. Lab leaders need to balance throughput with sensitivity, validate novel platforms against established benchmarks, and design workflows that scale without compromising traceability. Moreover, the convergence of next-generation sequencing, digital PCR, immunoassay platforms, and CRISPR-based detection tools is expanding analytical choices, creating opportunities to reduce time-to-release for biologics while demanding new competency in bioinformatics, assay qualification, and contamination risk management.

As biotechnology pipelines diversify into gene therapies, viral vectors, and complex biologics, detection and quantification practices will increasingly influence manufacturing cycle time, regulatory submissions, and patient safety expectations. Therefore, a strategic introduction to these technologies frames them as essential infrastructure for any modern biomanufacturing organization committed to quality and operational resilience.

How convergence of CRISPR, digital PCR, next-generation sequencing, and automation is fundamentally reshaping viral detection workflows, quality strategies, and regulatory readiness

The landscape of viral detection and quantification is being redefined by a confluence of technological innovation, regulatory emphasis, and evolving use cases within biomanufacturing. Rapidly maturing technologies such as CRISPR-based detection platforms and digital PCR are delivering single-molecule sensitivity in formats suitable for high-integrity environments, while next-generation sequencing platforms provide comprehensive genomic resolution that transforms root-cause analysis and viral safety testing. At the same time, immunoassay refinements and lateral flow innovations continue to offer cost-effective, high-throughput screening options for routine surveillance.

Transitioning from legacy approaches, industry leaders are integrating instruments, reagents, and software into cohesive workflows that prioritize automation, data integrity, and traceability. This shift is reinforced by regulatory agencies placing greater emphasis on robust viral safety programs and traceable analytical records, prompting investments in validated platforms and standardized protocols. Simultaneously, the rise of personalized medicines and gene therapies has introduced complex sample matrices and low-abundance targets that challenge conventional detection modalities, thereby accelerating adoption of highly sensitive molecular tools.

Taken together, these transformative shifts are driving a new operating paradigm in which analytical decisions are tightly coupled to manufacturing design, quality control strategies, and supply chain planning. Organizations that harness these shifts through early validation, cross-disciplinary training, and investment in integrated analytics are positioned to reduce risk, improve batch release efficiency, and sustain compliance in an increasingly demanding regulatory environment.

Evaluating the operational and strategic effects of layered United States tariff measures on procurement, supplier qualification, and supply chain resilience for critical detection assets

Cumulative tariff actions originating in the United States in 2025 have introduced layered complexity into sourcing strategies for instruments, reagents, and specialized consumables used in viral detection and quantification. The tariffs have increased the relative cost of imported diagnostic platforms and certain reagent classes, prompting procurement teams to reassess supplier portfolios, inventory policies, and qualification pathways. As a result, manufacturers and laboratories are balancing the trade-offs between near-term cost pressures and the imperative to maintain validated workflows and uninterrupted supply of critical materials.

In response, organizations are pursuing a variety of mitigation approaches. Some are accelerating qualification of alternative suppliers, including regional manufacturers and contract manufacturers that can meet performance and regulatory documentation requirements. Others are redesigning supply chain agreements to include longer lead times and strategic inventory buffers for high-risk consumables while prioritizing contracts with flexible delivery terms. Additionally, there is growing interest in consolidating reagent formats and platform convergence to reduce the diversity of SKUs that require cross-border movement, thereby simplifying compliance with tariff regimes and lowering logistical overhead.

From a strategic perspective, tariff-driven cost shifts are compelling industry stakeholders to strengthen supplier validation processes, expand technical transfer capabilities, and invest in modular platforms that can accommodate locally sourced reagents. Over the medium term, these adaptations may enhance resilience by reducing single-source dependencies, but in the near term they demand careful change control, revalidation planning, and stakeholder alignment to avoid disruptions to manufacturing timelines and product quality assurance.

Comprehensive segmentation insights connecting instruments, reagent ecosystems, technologies, applications, end users, and sample types to strategic assay selection and procurement

Insight into product segmentation reveals that decision-making is increasingly driven by the need to match analytical capability with application-specific requirements. Instrumentation and systems span CRISPR detection systems, digital PCR systems, immunoassay analyzers, next-generation sequencing platforms, real-time PCR systems, and thermal cyclers, each offering distinct performance profiles for sensitivity, throughput, and integration. Reagents and kits encompass immunoassay reagents, NGS library preparation kits, PCR master mixes, RNA extraction kits, and sequencing reagents, all of which are fundamental to assay consistency and lot-to-lot reproducibility. Software and services complete the product landscape by enabling data management, algorithmic interpretation, and validation support necessary for regulated contexts.

From a technology perspective, CRISPR technology, immunoassays, next-generation sequencing, and polymerase chain reaction approaches present divergent strengths and trade-offs. Immunoassays include chemiluminescent immunoassay, ELISA, and lateral flow assay variants that favor throughput and ease of use for screening, while next-generation sequencing modalities such as Illumina sequencing, Ion Torrent sequencing, and nanopore sequencing deliver granular genomic insights for characterization and root-cause analyses. Polymerase chain reaction techniques range from conventional PCR to digital PCR and real-time PCR, with each type serving different sensitivity and quantitation needs.

Application segmentation highlights use cases including gene therapy quality control, research applications, vaccine development, viral load monitoring, and viral safety testing, and these application needs directly influence which product and technology combinations are appropriate. End users such as academic and research institutions, contract research organizations, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies each have distinct operational constraints and regulatory expectations that shape procurement criteria. Finally, sample types including blood and plasma, environmental samples, respiratory samples, and tissue samples impose analytical challenges that determine extraction protocols, assay selection, and validation pathways. Understanding these interconnected segmentation layers enables more targeted platform selection and procurement strategies that align with performance requirements and regulatory obligations.

How distinct regional drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific are shaping procurement, validation, and supply chain strategies for detection capabilities

Regional dynamics are shaping both demand patterns and supply chain strategies for viral detection and quantification capabilities. In the Americas, innovation hubs and a dense network of contract development and manufacturing organizations drive demand for high-throughput platforms, advanced sequencing, and highly quantitative modalities that support complex biologics pipelines. This region also emphasizes rapid regulatory clarity and operational scalability, which influences supplier selection and validation timelines.

In Europe, the Middle East & Africa, regulatory harmonization challenges coexist with pockets of strong public health infrastructure and academic excellence that sustain demand for both research-grade and GMP-compliant analytical solutions. Organizations across this region are investing in modular laboratory automation and collaborative validation frameworks to meet diverse regulatory requirements while maintaining cross-border interoperability. In the Asia-Pacific region, rapid capacity expansion, a growing biopharmaceutical manufacturing base, and significant investment in local manufacturing capability are creating demand for cost-efficient reagents, adaptable platforms, and scalable software solutions. Supply chain strategies in Asia-Pacific often prioritize local sourcing and regional partnerships to optimize costs and reduce exposure to international trade policy shifts.

Taken together, these regional differentiators influence supplier network design, validation strategies, and decisions about onshoring versus international procurement. Because regulatory expectations and infrastructure maturity vary across these geographies, manufacturers and laboratories must align analytical strategies with regional operational realities to ensure continuity, compliance, and time-sensitive program delivery.

Strategic competitive dynamics among instrument leaders, reagent specialists, and platform innovators shaping partnerships, validation services, and long-term procurement decisions

Competitive dynamics in the viral detection and quantification ecosystem reflect a mix of established instrument providers, reagent specialists, and emerging platform innovators. Leading instrument makers continue to invest in platform convergence, integrating molecular, sequencing, and immunoassay modalities to offer broader analytical footprints that appeal to both research and regulated manufacturing customers. At the same time, specialized reagent and kit suppliers focus on formulation consistency, lot control, and regulatory documentation to support validated workflows in GMP environments. Startups and scale-ups are pushing boundaries with CRISPR-based assays, nanopore sequencing improvements, and software-driven analytics that promise faster problem resolution and more actionable datasets.

Partnerships between hardware vendors, reagent manufacturers, and software developers are increasingly common, enabling end-to-end solutions that reduce complexity for end users. Strategic alliances with contract research organizations and contract development and manufacturing organizations also facilitate hands-on validation work and accelerate adoption in commercial manufacturing settings. Vendors that provide comprehensive validation packages, responsive technical support, and cloud-enabled data management often gain a competitive edge when customers evaluate total cost of ownership alongside long-term regulatory commitments.

Ultimately, companies that balance platform performance with serviceability, regulatory support, and supply continuity are best positioned to win long-term engagements. Providers that demonstrate responsiveness to change control requests, offer flexible supply arrangements, and invest in interoperable software ecosystems will be more successful in meeting the evolving needs of biomanufacturing stakeholders.

Concrete, high-impact recommendations for biomanufacturing leaders to strengthen assay validation, supplier diversification, automation interoperability, and regulatory data integrity

Industry leaders should prioritize a set of actionable initiatives to strengthen analytical robustness, supply resilience, and regulatory preparedness across viral detection and quantification programs. First, instituting cross-functional governance that coordinates quality, manufacturing, and analytical development teams will reduce silos and accelerate decision-making for assay selection, change control, and technical transfers. Embedding subject matter experts in validation planning early ensures assay performance criteria are aligned with release requirements and mitigates downstream surprises.

Second, organizations should diversify qualified supplier lists and pursue redundancy for critical reagents and consumables while developing clear requalification pathways to minimize production disruptions. Strategic inventory governance, combined with scenario-based stress testing of supplier continuity, can reduce operational risk without inflating carrying costs. Third, investing in platform interoperability and modular automation reduces friction when swapping instruments or reagent formats, enabling more agile responses to supply shocks or regulatory changes. Ensuring data integrity through validated software, robust audit trails, and standardized reporting templates will further enhance regulatory confidence and inspection readiness.

Finally, cultivating partnerships with external laboratories and contract organizations for surge capacity, and pursuing incremental adoption of high-sensitivity techniques such as digital PCR and targeted sequencing for critical release assays, will improve sensitivity and diagnostic resolution. Executed together, these recommendations create a resilient, compliant, and efficient analytical foundation that supports accelerated program development while safeguarding product quality.

A rigorous mixed-methods research approach combining stakeholder interviews, technical literature synthesis, regulatory alignment, and scenario-based supply chain analysis

The research methodology underpinning this analysis integrates a structured mix of qualitative and quantitative evidence to deliver a robust, operationally relevant perspective. Primary inputs were gathered through targeted interviews with laboratory directors, quality assurance leaders, procurement managers, and technical subject matter experts who provided insights into platform performance, validation challenges, and supplier dynamics. These firsthand accounts were synthesized to identify common pain points and adoption drivers across different end users and applications.

Secondary information was compiled from peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available product documentation to validate technological capabilities and typical use-case scenarios. The analysis also included scenario-based supply chain assessments to evaluate the potential operational implications of tariff changes and supplier disruptions, informed by industry-standard supply continuity practices. Analytical rigor was maintained through cross-validation of qualitative findings against documented product specifications, regulatory expectations, and common validation protocols used in regulated environments.

Throughout the research cycle, emphasis was placed on transparency of assumptions, traceable evidence trails for assertions, and alignment with practical implementation constraints faced by biomanufacturing organizations. This mixed-methods approach ensures that the conclusions and recommendations are both evidence-based and directly applicable to operational decision-making.

A conclusive synthesis emphasizing how integrated detection strategies, supplier resilience, and advanced analytics will determine biomanufacturing success and regulatory readiness

In conclusion, viral detection and quantification are no longer ancillary activities but core elements of biomanufacturing quality and operational strategy. The integration of sensitive molecular tools, automated workflows, and advanced analytics is delivering tangible improvements in contamination control, batch release processes, and regulatory traceability. At the same time, trade policy developments and supply chain complexity require proactive supplier qualification, flexible validation planning, and investment in interoperable platforms to sustain uninterrupted operations.

Organizations that adopt a strategic approach-combining cross-functional governance, diversified procurement, targeted adoption of high-sensitivity techniques, and validated data management systems-will be better positioned to manage risk and accelerate product development cycles. As technologies continue to evolve, continuous learning, partnership-driven validation efforts, and scenario planning will be essential to maintaining both compliance and competitive advantage. Ultimately, the ability to translate analytical capability into robust manufacturing practice will determine which organizations consistently deliver high-quality biologics and advanced therapeutics to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biomanufacturing Viral Detection & Quantification Market, by Product

  • 8.1. Instruments & Systems
    • 8.1.1. CRISPR Detection Systems
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. Thermal Cyclers
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Biomanufacturing Viral Detection & Quantification Market, by Technology

  • 9.1. Crispr Technology
  • 9.2. Immunoassay
    • 9.2.1. Chemiluminescent Immunoassay
    • 9.2.2. Elisa
    • 9.2.3. Lateral Flow Assay
  • 9.3. Next Generation Sequencing
    • 9.3.1. Illumina Sequencing
    • 9.3.2. Ion Torrent Sequencing
    • 9.3.3. Nanopore Sequencing
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Pcr
    • 9.4.2. Digital Pcr
    • 9.4.3. Real-Time Pcr

10. Biomanufacturing Viral Detection & Quantification Market, by Sample Type

  • 10.1. Blood & Plasma
  • 10.2. Environmental Samples
  • 10.3. Respiratory Samples
  • 10.4. Tissue Samples

11. Biomanufacturing Viral Detection & Quantification Market, by Application

  • 11.1. Gene Therapy Quality Control
  • 11.2. Research Applications
  • 11.3. Vaccine Development
  • 11.4. Viral Load Monitoring
  • 11.5. Viral Safety Testing

12. Biomanufacturing Viral Detection & Quantification Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Contract Research Organizations
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals & Clinics
  • 12.5. Pharmaceutical & Biotechnology Companies

13. Biomanufacturing Viral Detection & Quantification Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biomanufacturing Viral Detection & Quantification Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biomanufacturing Viral Detection & Quantification Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biomanufacturing Viral Detection & Quantification Market

17. China Biomanufacturing Viral Detection & Quantification Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Avantor, Inc.
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. BioReliance Corporation
  • 18.9. Creative Diagnostics, Inc.
  • 18.10. Danaher Corporation
  • 18.11. Eurofins Scientific SE
  • 18.12. FUJIFILM Diosynth Biotechnologies, Inc.
  • 18.13. Genscript Biotech Corporation
  • 18.14. Illumina, Inc.
  • 18.15. Lonza Group Ltd.
  • 18.16. Merck KGaA
  • 18.17. New England Biolabs, Inc.
  • 18.18. Norgen Biotek Corp.
  • 18.19. Pall Corporation
  • 18.20. PerkinElmer, Inc.
  • 18.21. Promega Corporation
  • 18.22. QIAGEN N.V.
  • 18.23. Roche Holding AG
  • 18.24. Sartorius AG
  • 18.25. SGS Societe Generale de Surveillance S.A.
  • 18.26. Takara Holdings, Inc.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. Virapur, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY BLOOD & PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY BLOOD & PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY BLOOD & PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESPIRATORY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESPIRATORY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESPIRATORY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 238. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 248. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)

TABLE 249